Sosei Heptares (the corporate brand of Sosei Group Corporation) is a research-focused biotechnology group, publicly listed in Japan (TSE: 4565) and with sites in Cambridge, Tokyo, and London (UK).
Our mission is to make a significant contribution to improving the quality of life and health of people around the world. To achieve this, we will discover, design and develop the most innovative and effective medicines for patients worldwide, through our world-leading patent-protected technology and platform.
Our primary focus is the discovery and early development of new medicines originating from our proprietary G Protein-Coupled Receptor (GPCR)-targeted StaR® technology and Structure-Based Drug Design (SBDD) platform capabilities. We are advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including immuno-oncology, immunology, gastroenterology, inflammation, CNS and other rare/specialty indications.
We have established partnerships with some of the world’s leading pharmaceutical companies, including AbbVie, AstraZeneca, Biohaven, Genentech (Roche), GSK, Novartis, Pfizer and Takeda and additionally with multiple emerging technology companies. Sosei Heptares is headquartered in Tokyo, Japan with corporate and R&D facilities in Cambridge, UK.
Sosei Heptares has approximately 180 employees based at its new R&D research facility at Granta Park. The size of the company ensures a transparent linkage between all activities from early discovery through translational medicine and into clinical development.
Do you feel passionate about the possibilities to make a meaningful difference to patients’ lives? Are you driven by scientific challenges? If you are an exceptional scientist who is seeking drug discovery opportunities in the Neuroscience therapeutic area, this role may be for you.
At Sosei Heptares we believe in targeting GPCRs to deliver transformative medicines for patients. To do this our world class scientists have developed a proprietary structure based drug design (SBDD) platform to improve the design of safer & more effective GPCR drugs. Our approach has been validated with multiple programs progressing from structure to the clinic.
This is an exciting time to join our company as we enter the next phase of growth. We have recently developed a new Translational Medicine
function to accelerate and deliver programs into early clinical development to POM/POC, underpinned by a strong understanding of the biological mechanism of action. This position reflects our commitment to secure world class translational medicine capabilities to support one of our core therapeutic areas in Neuroscience.
Come and join us in our R&D team in Cambridge UK and realise the opportunity to put your outstanding scientific experience into practice to deliver transformative GPCR medicines to patients.
We are seeking an individual passionate about advancing novel therapies and biomarker strategies for the treatment of neurodegenerative and neuropsychiatric diseases. This highly motivated individual will serve as the in vivo pharmacology lead on neuroscience discovery projects and work cross-functionally to develop and implement preclinical study plans and strategies. They will work closely with CRO/academic partners to design native cell- and in vivo studies to support CNS projects. They will also support efforts to develop translational biomarker strategies for CNS programs. This individual will also help to develop and embed data management processes for in vivo pharmacology data across the portfolio.
The ideal candidate will have:
· PhD or a BSc with a minimum of 2 years drug discovery or development experience in an Neuroscience-related therapeutic area. Equivalent experience gained in an academic background may also be considered.
· Good understanding of Home Office legislation governing in vivo research and direct experience in the experimental design and oversight of in vivo studies.
· Hands-on experience in managing outsourced studies with CROs or academic partners
· Proven ability to work effectively in a multidisciplinary matrix team environment; Excellent interpersonal skills
· Experience of carrying out both independent and collaborative research
· Proven ability in data analysis and problem-solving
· Excellent organisational and data management skills
This is an exciting opportunity to work across diverse functional groups within Sosei Heptares and with external industrial and academic collaborators. Working within research-phase and development-phase project teams, your primary responsibility will be to shape and deliver translational Neuroscience research plans. You will:
· Work collaboratively with internal Sosei Heptares colleagues and external (academic and industrial) collaborators to support Neuroscience programs.
· Lead and oversee the development and optimisation of assays at CROs. Be responsible for leading the design, delivery, analysis, and reporting of outsourced assays.
· Use literature and other approaches to identify new targets and embed translational plans for programs
· Develop robust TE biomarkers strategy to support drug discovery programmes.
· Effectively manage data arising from in vivo pharmacology studies.
The successful candidate will be employed by Heptares Therapeutics Ltd, a UK wholly owned subsidiary of Sosei Group Corporation.
Sosei Heptares is committed to building a diverse and ambitious workforce, and to promoting equal opportunities in employment. We recognize that diverse and inclusive teams build a stronger and more innovative company. Therefore, all qualified applicants will be considered for employment: we do not discriminate based on age, disability, gender reassignment, marriage and civil partnership, pregnancy and maternity, race, religion or belief, sex, sexual orientation, or any other classification prescribed by law.
Applications should include a covering letter, providing a short description of the background to their interest in the role, with curriculum vitae. Please apply through our on-line jobs’ portal with your application in pdf format, quoting reference number 2023-SS-TBN-TM. The closing date for applications is 28th February 2023.
Sosei Heptares does not accept speculative or unsolicited CVs from agencies. All speculative or unsolicited CVs submitted without an agreement in place will be considered Sosei Heptares' property and will not obligate us to pay a referral fee.
For more information about Sosei Heptares and how we use your data please go to: https://soseiheptares.com/privacy-notice